A personalised cancer treatment developed by Moderna and Merck has shown positive trial results in helping prevent high-risk melanoma from returning after surgery.
A press release from Moderna and Merck is genuinely exciting news for people affected by melanoma. For many patients, one of the biggest fears after having their melanoma removed is that it will come back or spread. The possibility of a treatment designed around the individual characteristics of a person’s own cancer is an important step forward in personalised melanoma treatment.
The ‘Phase 3’ results announced by Moderna and Merck are particularly encouraging, showing a benefit in reducing both recurrence and distant spread. This is an important milestone for melanoma research. However, we must not get ahead of the evidence. These are topline results, with the full clinical data yet to be published, and overall survival is still being assessed. This not yet an approved treatment and will need to be reviewed by the regulators and be progressed through the proper channels if approved.
We should be hopeful but measured. For people living with melanoma today, this news offers real hope — and underlines why continued investment in research matters. Our priority must be ensuring advances like this ultimately become safe, effective and importantly accessible treatments for patients.
#ResearchMatters
